What's going on, and what to make of it.
politics
Eleven states are offering state-funded premium assistance to ACA enrollees in 2027 after enhanced federal subsidies expired. Rhode Island and Virginia are new to the list, and California expanded eligibility.
business
The FDA is requiring new safety warnings on all GLP-1 weight-loss and diabetes drugs after finding evidence of a rare eye condition that can cause permanent vision loss. Novo Nordisk and Eli Lilly disputed a causal link.
business
Moderna beat third-quarter revenue and earnings estimates by wide margins and raised its 2026 sales growth guidance to 15-25%. New vaccine launches and geographic expansion drove the surprise.
business
Novo Nordisk posted third-quarter earnings ahead of expectations, driven by strong sales of its Wegovy pill. The drugmaker raised its full-year outlook and said it holds 80% of the U.S. GLP-1 market.
business
Novonesis CEO Ester Baiget says dietary supplements can complement GLP-1 weight-loss drugs, citing an ongoing study with Novo Nordisk. The global supplements market is projected to double by 2033.
health
Eli Lilly's daily pill Foundayo reduced sleep apnea severity by 44% in a phase 3 trial, paving the way for FDA approval. The drug also produced 11% weight loss, positioning it against injected GLP-1 competitors.
health
The FDA added a warning about a rare eye condition that can cause sudden vision loss and blindness to the labels of all GLP-1 drugs, including Ozempic, Wegovy, Zepbound and Mounjaro, after reviewing more than 125 clinical trials.